Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Minaris and bluebird bio Enter Manufacturing Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Minaris and bluebird bio Enter Manufacturing Pact

The CDMO will be the commercial manufacturer in Europe for Skysona, bluebird bio’s gene therapy for CALD.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Minaris Regenerative Medicine GmbH, a leading contract development and manufacturing organization (CDMO) for the cell and gene therapy industry, will be the commercial manufacturer in Europe for Skysona (elivaldogene autotemcel, Lenti-D), a product of bluebird bio, Inc. The European Commission (EC) has granted marketing authorization for Skysona, the first and only gene therapy for patients with Early Cerebral Adrenoleukodystrophy (CALD), a life-threatening progressive neurodegenerative disease.
 
“We are proud to contribute to the fight against this devastating disease in children and to support bluebird bio also with their second commercial product,” said Dusan Kosijer, CEO, Minaris Regenerative Medicine GmbH.
 
Andrew Obenshain, president, severe genetic diseases, bluebird bio, said, “Minaris is our long-standing partner for bringing gene therapies to patients in Europe. Our collaboration will be integral as we work to provide Skysona to the community who faces the rapid and irreversible effects of CALD.”
 
In 2016, Minaris and bluebird bio entered into a strategic manufacturing partnership for commercial production of Zynteglo for transfusion-dependent β-thalassemia (TDT) and Skysona for CALD in Europe. In 2020, the companies expanded their manufacturing partnership to include late stage and commercial drug product manufacturing both in Europe and the USA (at Minaris Regenerative Medicine, LLC) of LentiGlobin for the treatment of patients with sickle cell disease (SCD).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters